Premium
CLINICAL TRIAL OF A NEW ANTIBIOTIC
Author(s) -
Newell Andbew C.
Publication year - 1970
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1970.tb50015.x
Subject(s) - clindamycin , antibiotics , medicine , erythromycin , haemophilus influenzae , clinical trial , surgery , microbiology and biotechnology , biology
A clinical trial of clindamycin (“Daiacin C”, “Cleosin”) was undertaken at The Geelong Hospital. Forty‐two patients received 45 courses of treatment. Patients selected for the trial exhibited a wide spectrum of major and minor illness, and included three suffering from osteomyelitis and eight with Infections due to Haemophilus influenzae. Thirty‐ two of the 42 patients responded satisfactorily. Two developed gastro‐intestinal side effects and four exhibited a minor transient rise in SGOT leveis. Four patients, two suffering from staphylococcal infections and two from hæmophilus infections, developed antibiotic resistance to both clindamycin and erythromycin after five, seven, eight and ten days of treatment respectively. There were no other side effects or untoward reactions of the medication. Clindamycin is an effective medium‐spectrum antibiotic suitable for the treatment of a wide range of major and minor illness involving Gram‐positive cocci or hæmophilus Infections. It is well tolerated, and the occurrence of two cases of gastro‐intestinal reaction in a total of 45 courses of treatment would compare favourably with the side effects of other orally administered antibiotics.